|
|
| (2 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[List of chemotherapy regimens]] |
| {{SI}}
| |
| {{CMG}}
| |
| | |
| ==Overview==
| |
| A '''chemotherapy regimen''' is a [[regimen]] for [[chemotherapy]] defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations. In modern [[oncology]] almost all regimens in use combine several [[list of chemotherapeutic agents|chemotherapy drugs]] in [[combination chemotherapy]]. The majority of drugs used in cancer chemotherapy are [[cytostatic]].
| |
| | |
| A fundamental philosophy of [[oncology#Specialties|medical oncology]], including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens.<ref>Mayer, RJ, Targeted therapy for advanced colorectal cancer -- more is not always better, N Engl J Med. 2009;360:623 which is a [possibly critical and not peer reviewed] comment to [http://www.ncbi.nlm.nih.gov/pubmed/19196673 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.]</ref>
| |
| | |
| The first successful combination chemotherapy was [[MOPP (medicine)|MOPP]] introduced in 1963 for lymphomas.
| |
| | |
| The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow.<ref>[http://www.cancer.net/all-about-cancer/cancernet-feature-articles/treatments-tests-and-procedures/explaining-maintenance-therapy Cancer.net - Explaining Maintenance Therapy]</ref>
| |
| | |
| Chemotherapy regimens are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments.<ref>[http://hemonc.org/wiki/Hodgkin_lymphoma BEACOPP chemotherapy regimen]</ref>
| |
| | |
| There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either [[generic drug|generic]] or [[brand name]]s may be used for acronyms. This page merely lists commonly used conventions.
| |
| | |
| ==List of Chemotherapy Regimens==
| |
| | |
| {| class="wikitable"
| |
| ! Name !! Components !! Example of uses, and other notes
| |
| |-
| |
| | [[7+3 (chemotherapy)|7+3]], also known as [[DA (chemotherapy)|DA]] or [[DAC (chemotherapy)|DAC]] in case of [[daunorubicin]], or [[IA (chemotherapy)|IA]] or [[IAC (chemotherapy)|IAC]] in case of [[idarubicin]] use
| |
| | 7 days of Ara-C ([[cytarabine]]) plus 3 days of an [[anthracycline]] [[antibiotic]], either [[daunorubicin]] ([[DA (chemotherapy)|DA]] or [[DAC (chemotherapy)|DAC]] variant) or [[idarubicin]] ([[IA (chemotherapy)|IA]] or [[IAC (chemotherapy)|IAC]] variant)
| |
| | [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
| |
| |-
| |
| | [[ABVD]]
| |
| | [[doxorubicin]] (Adriamycin), [[bleomycin]], [[vinblastine]], [[dacarbazine]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | AC
| |
| | [[doxorubicin]] (Adriamycin), [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | BACOD
| |
| | [[bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| |
| |
| |
| |-
| |
| | [[BEACOPP]]
| |
| | [[bleomycin]], [[etoposide]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | BEP
| |
| | [[bleomycin]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| |
| | [[testicular cancer]], [[germ cell tumor]]s
| |
| |-
| |
| | CA
| |
| | [[cyclophosphamide]], [[doxorubicin]] (Adriamycin) (same as AC)
| |
| | [[breast cancer]]
| |
| |-
| |
| | CAF
| |
| | [[cyclophosphamide]], [[doxorubicin]] (Adriamycin), [[fluorouracil]] (5-FU)
| |
| | [[breast cancer]]
| |
| |-
| |
| | [[CAPOX]] or XELOX
| |
| | [[capecitabine]] and [[oxaliplatin]]
| |
| | [[colorectal cancer]]
| |
| |-
| |
| | CAV
| |
| | [[cyclophosphamide]], [[doxorubicin]] (Adriamycin), [[vincristine]]
| |
| | [[lung cancer]]
| |
| |-
| |
| | [[CBV (chemotherapy)|CBV]]
| |
| | [[cyclophosphamide]], [[BCNU|BCNU (carmustine)]], VP-16 ([[etoposide]])
| |
| | [[lymphoma]]
| |
| |-
| |
| | [[CHOEP]]
| |
| | [[cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[CEPP]]
| |
| | [[cyclophosphamide]], [[etoposide]], [[procarbazine]], [[prednisone]]
| |
| | [[Non-Hodgkin Lymphoma]]s
| |
| |-
| |
| | ChlVPP/EVA
| |
| | [[chlorambucil]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]], [[etoposide]], [[vinblastine]], [[doxorubicin]] (Adriamycin)
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | [[CHOP]]
| |
| | [[cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| |
| | [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | [[CHOP-R]] or [[R-CHOP]]
| |
| | [[CHOP]] + [[rituximab]]
| |
| | [[B cell]] [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | ClaPD
| |
| | [[clarithromycin]], [[pomalidomide]], [[dexamethasone]]
| |
| |
| |
| |-
| |
| | [[cyclophosphamide, methotrexate and fluorouracil|CMF]]
| |
| | [[cyclophosphamide]], [[methotrexate]], [[fluorouracil]] (5-FU)
| |
| | [[breast cancer]]
| |
| |-
| |
| | CMV
| |
| | [[cisplatin]], [[methotrexate]], [[vinblastine]]
| |
| |
| |
| |-
| |
| | [[CHOP|COP]] or [[CHOP|CVP]]
| |
| | [[cyclophosphamide]], Oncovin ([[vincristine]]), [[prednisone]]
| |
| | [[non-Hodgkin lymphoma]] in patients with history of [[cardiovascular disease]]
| |
| |-
| |
| | [[COPP (chemotherapy)|COPP]]
| |
| | [[cyclophosphamide]], Oncovin ([[vincristine]]), [[procarbazine]], [[prednisone]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | CT or TC
| |
| | [[docetaxel]] (Taxotere), [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | CTD
| |
| | [[cyclophosphamide]], [[thalidomide]], [[dexamethasone]]
| |
| | [[AL amyloidosis]]
| |
| |-
| |
| | [[Hyper-CVAD|CVAD and Hyper-CVAD]]
| |
| | [[cyclophosphamide]], [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| |
| | aggressive [[non-Hodgkin lymphoma]], [[lymphoblastic lymphoma]], some forms of [[leukemia]]
| |
| |-
| |
| | CYBORD
| |
| | [[cyclophosphamide]], [[bortezomib]], [[dexamethasone]]
| |
| |
| |
| |-
| |
| | [[DA (chemotherapy)|DA]] or [[DAC (chemotherapy)|DAC]]
| |
| | [[daunorubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of [[7+3 (chemotherapy)|7+3]] regimen
| |
| | [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
| |
| |-
| |
| | DCEP
| |
| | [[dexamethasone]], [[cyclophosphamide]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| |
| |
| |
| |-
| |
| | [[DHAP_(chemotherapy)|DHAP]]
| |
| | [[dexamethasone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[DHAP-R]] or [[R-DHAP]]
| |
| | [[dexamethasone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | DICE
| |
| | [[dexamethasone]], [[ifosfamide]], [[cisplatin]], [[etoposide]] (VP-16)
| |
| | aggressive relapsed [[lymphomas]], progressive [[neuroblastoma]]
| |
| |-
| |
| | [[DT-PACE]]
| |
| | [[dexamethasone]], [[thalidomide]], [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| | [[multiple myeloma]]
| |
| |-
| |
| | EC
| |
| | [[epirubicin]], [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | ECF
| |
| | [[epirubicin]], [[cisplatin]], [[fluorouracil]] (5-FU)
| |
| | [[gastric cancer]] and [[esophageal cancer]]
| |
| |-
| |
| | EOX
| |
| | [[epirubicin]], [[oxaliplatin]], [[capecitabine]]
| |
| |
| |
| |-
| |
| | EP
| |
| | [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| |
| | [[testicular cancer]], [[germ cell tumor]]s
| |
| |-
| |
| | [[EPOCH (chemotherapy)|EPOCH]]
| |
| | [[etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[EPOCH-R]] or [[R-EPOCH]]
| |
| | [[etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]] plus [[rituximab]]
| |
| | [[B cell]] [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[ESHAP]]
| |
| | [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]]
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | [[ESHAP-R]] or [[R-ESHAP]]
| |
| | [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]
| |
| |-
| |
| | FAM
| |
| | [[fluorouracil]], [[doxorubicin]] (Adriamycin), [[mitomycin]]
| |
| |
| |
| |-
| |
| | [[FCM (chemotherapy)|FCM]] or [[FMC (chemotherapy)|FMC]]
| |
| | [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | [[FCM-R]] or [[R-FCM]] or [[R-FMC]] or [[FMC-R]]
| |
| | [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] plus [[rituximab]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | [[FM (chemotherapy)|FM]]
| |
| | [[fludarabine]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | [[FM-R]] or [[R-FM]] or [[RFM (chemotherapy)|RFM]] or [[FMR (chemotherapy)|FMR]]
| |
| | [[fludarabine]], [[mitoxantrone]], and [[rituximab]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | FEC
| |
| | [[fluorouracil]] (5-FU), [[epirubicin]], [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | FL (also known as Mayo)
| |
| | [[fluorouracil]] (5-FU), leucovorin ([[folinic acid]])
| |
| | [[colorectal cancer]]
| |
| |-
| |
| | [[FLAG (chemotherapy)|FLAG]]
| |
| | [[fludarabine]], [[cytarabine]], [[G-CSF]]
| |
| | [[relapse]]d or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
| |
| |-
| |
| | [[FLAG-Ida]] or [[FLAG-IDA]] or [[IDA-FLAG]] or [[Ida-FLAG]]
| |
| | [[fludarabine]], [[cytarabine]], [[idarubicin]], [[G-CSF]]
| |
| | [[relapse]]d or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
| |
| |-
| |
| | [[FLAG-Mito]] or [[FLAG-MITO]] or [[Mito-FLAG]] or [[MITO-FLAG]] or [[FLANG]]
| |
| | [[mitoxantrone]], [[fludarabine]], [[cytarabine]], [[G-CSF]]
| |
| | [[relapse]]d or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
| |
| |-
| |
| | [[FLAMSA]]
| |
| | [[fludarabine]], [[cytarabine]], [[amsacrine]]
| |
| | [[myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | [[FLAMSA-BU]] or [[FLAMSA-Bu]]
| |
| | [[fludarabine]], [[cytarabine]], [[amsacrine]], [[busulfan]]
| |
| | [[myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | [[FLAMSA-MEL]] or [[FLAMSA-Mel]]
| |
| | [[fludarabine]], [[cytarabine]], [[amsacrine]], [[melphalan]]
| |
| | [[myelodysplastic syndrome]], [[acute myeloid leukemia]]
| |
| |-
| |
| | [[FOLFIRI]]
| |
| | [[fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]]
| |
| | [[colorectal cancer]]
| |
| |-
| |
| | [[FOLFIRINOX]]
| |
| | [[fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]], [[oxaliplatin]]
| |
| | [[pancreatic cancer]]
| |
| |-
| |
| | [[FOLFOX]]
| |
| | [[fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[oxaliplatin]]
| |
| | [[colorectal cancer]]
| |
| |-
| |
| | GC
| |
| | [[gemcitabine]], [[cisplatin]]
| |
| |
| |
| |-
| |
| | [[GVD (chemotherapy)|GVD]]
| |
| | [[gemcitabine]], [[vinorelbine]], pegylated liposomal [[doxorubicin]]
| |
| | [[Hodgkin lymphoma]]
| |
| |-
| |
| | [[GemOx]] or [[GEMOX]]
| |
| | [[gemcitabine]], [[oxaliplatin]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[GemOx-R]] or [[GEMOX-R]] or [[R-GemOx]] or [[R-GEMOX]]
| |
| | [[gemcitabine]], [[oxaliplatin]], [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]s
| |
| |-
| |
| | [[IA (chemotherapy)|IA]] or [[IAC (chemotherapy)|IAC]]
| |
| | [[idarubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of classical [[7+3 (chemotherapy)|7+3]] regimen
| |
| | [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
| |
| |-
| |
| | [[ICE (chemotherapy)|ICE]]
| |
| | [[ifosfamide]], [[carboplatin]], [[etoposide]] (VP-16)
| |
| | aggressive [[lymphomas]], progressive [[neuroblastoma]]
| |
| |-
| |
| | [[ICE-R]] or [[R-ICE]] or [[RICE (chemotherapy)|RICE]]
| |
| | [[ICE (chemotherapy)|ICE]] + [[rituximab]]
| |
| | high-risk progressive or recurrent [[lymphomas]]
| |
| |-
| |
| | [[IFL (chemotherapy)|IFL]]
| |
| | [[irinotecan]], leucovorin ([[folinic acid]]), [[fluorouracil]]
| |
| | [[colorectal cancer]]
| |
| |-
| |
| | m-BACOD
| |
| | [[methotrexate]], [[bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| |
| | [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | MACOP-B
| |
| | [[methotrexate]], leucovorin ([[folinic acid]]), [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| |
| | [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | [[MINE (chemotherapy)|MINE]]
| |
| | [[mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]]
| |
| | [[Non-Hodgkin lymphoma]]s and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
| |
| |-
| |
| | [[MINE-R]] or [[R-MINE]]
| |
| | [[mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]] plus [[rituximab]]
| |
| | [[Non-Hodgkin lymphoma]]s and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
| |
| |-
| |
| | MMM
| |
| | [[mitomycin]], [[methotrexate]], [[mitoxantrone]]
| |
| |
| |
| |-
| |
| | [[MOPP (chemotherapy)|MOPP]]
| |
| | [[mechlorethamine]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | MVAC
| |
| | [[methotrexate]], [[vinblastine]], [[adriamycin]], [[cisplatin]]
| |
| | advanced [[bladder cancer]]<ref>[http://www.cancernetwork.com/bladder-cancer/content/article/10165/71963 MVAC Still the ‘Best Treatment’ for Advanced Bladder Cancer Patients. 1999]</ref>
| |
| |-
| |
| | MVP
| |
| | [[mitomycin]], [[vindesine]], [[cisplatin]]
| |
| |
| |
| |-
| |
| | NP
| |
| | [[cisplatin]], [[vinorelbine]]
| |
| |
| |
| |-
| |
| | PACE
| |
| | [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| |
| |
| |-
| |
| | PCV
| |
| | [[Procarbazine]], CCNU ([[lomustine]]), [[vincristine]]
| |
| | [[brain tumor]]s
| |
| |-
| |
| | PEB
| |
| | [[cisplatin]], [[etoposide]], [[bleomycin]]
| |
| |
| |
| |-
| |
| | PEI
| |
| | [[cisplatin]], [[etoposide]], [[ifosfamide]]
| |
| |
| |
| |-
| |
| | POMP
| |
| | 6-[[mercaptopurine]] (Purinethol), [[vincristine]] (Oncovin), [[methotrexate]], and [[prednisone]]
| |
| | acute adult [[leukemia]]<ref>[http://onlinelibrary.wiley.com/doi/10.1002/1097-0142%28197307%2932:1%3C69::AID-CNCR2820320109%3E3.0.CO;2-0/abstract POMP combination chemotherapy of adult acute leukemia.]</ref>
| |
| |-
| |
| | ProMACE-MOPP
| |
| | [[methotrexate]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]] + [[MOPP (medicine)|MOPP]]
| |
| | [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | ProMACE-CytaBOM
| |
| | [[prednisone]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine]] (Oncovin), [[methotrexate]], [[leucovorin]]
| |
| | [[non-Hodgkin lymphoma]]
| |
| |-
| |
| | RdC
| |
| | [[lenalidomide]] (Revlimid), [[dexamethasone]], [[cyclophosphamide]]
| |
| |
| |
| |-
| |
| | [[R-DHAP]] or [[DHAP-R]]
| |
| | [[rituximab]] + [[DHAP (chemotherapy)|DHAP]]; that is, [[rituximab]], [[dexamethasone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]]
| |
| |
| |
| |-
| |
| | [[R-FCM]] or [[FCM-R]]
| |
| | [[rituximab]] + [[FCM (chemotherapy)|FCM]]; that is, [[rituximab]], [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| |
| | [[B cell]] non-Hodgkin lymphoma
| |
| |-
| |
| | [[R-ICE]] or [[ICE-R]] or [[RICE (chemotherapy)|RICE]]
| |
| | [[rituximab]] + [[ICE chemotherapy regimen|ICE]]; that is, [[rituximab]], [[ifosfamide]], [[carboplatin]], [[etoposide]]
| |
| | high-risk progressive or recurrent [[lymphomas]]
| |
| |-
| |
| | RVD
| |
| | [[lenalidomide]] (Revlimid), [[bortezomib]], [[dexamethasone]]
| |
| |
| |
| |-
| |
| | [[Stanford V]]
| |
| | [[doxorubicin]] (Adriamycin), [[mechlorethamine]], [[bleomycin]], [[vinblastine]], [[vincristine]], [[etoposide]], [[prednisone]]
| |
| | [[Hodgkin lymphoma]]
| |
| |-
| |
| | TAC or ACT
| |
| | [[docetaxel]] (Taxotere) or [[paclitaxel]] (Taxol), [[doxorubicin]] (Adriamycin), [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | TC or CT
| |
| | [[docetaxel]] (Taxotere), [[cyclophosphamide]]
| |
| | [[breast cancer]]
| |
| |-
| |
| | [[TCH (chemotherapy)|TCH]]
| |
| | [[paclitaxel]] (Taxol), [[carboplatin]], [[trastuzumab]] (Herceptin)
| |
| | [[breast cancer]] with positive [[HER2/neu]] receptor
| |
| |-
| |
| | Thal/Dex
| |
| | [[thalidomide]], [[dexamethasone]]
| |
| | [[multiple myeloma]]
| |
| |-
| |
| | TIP
| |
| | [[paclitaxel]] (Taxol), [[ifosfamide]], platinum agent [[cisplatin|cisplatin (Platinol)]]
| |
| | [[testicular cancer]], [[germ cell tumor]]s in salvage therapy
| |
| |-
| |
| | {{visible anchor|EE-4A}}
| |
| | [[vincristine]], [[actinomycin]]<ref name=nci/>
| |
| | [[Wilms' tumor]]<ref name=nci>[http://www.cancer.gov/cancertopics/pdq/treatment/wilms/HealthProfessional/Page5 Treatment of Wilms Tumor] at [[National Cancer Institute]]. Last Modified: 03/29/2012</ref>
| |
| |-
| |
| | {{visible anchor|DD-4A}}
| |
| | [[vincristine]], [[actinomycin]], [[doxorubicin]] (Adriamycin)<ref name=nci/>
| |
| | [[Wilms' tumor]]<ref name=nci/>
| |
| |-
| |
| | VAC
| |
| | [[vincristine]], [[actinomycin]], [[cyclophosphamide]]
| |
| | [[rhabdomyosarcoma]]
| |
| |-
| |
| | VAD
| |
| | [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| |
| | [[multiple myeloma]]
| |
| |-
| |
| | [[VAMP Regimen|VAMP]]
| |
| | one of 3 combinations of [[vincristine]] and others
| |
| | [[Hodgkin's lymphoma]], [[leukemia]], [[multiple myeloma]]
| |
| |-
| |
| | {{visible anchor|Regimen I}}
| |
| | [[vincristine]], [[doxorubicin]] (Adriamycin), [[etoposide]], [[cyclophosphamide]]
| |
| | [[Wilms' tumor]]<ref name=nci/>
| |
| |-
| |
| | VAPEC-B
| |
| | [[vincristine]], [[doxorubicin]] (Adriamycin), [[prednisone]], [[etoposide]], [[cyclophosphamide]], [[bleomycin]]
| |
| | [[Hodgkin's lymphoma]]
| |
| |-
| |
| | VD-PACE
| |
| | [[bortezomib]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| |
| |
| |-
| |
| | VIFUP
| |
| | [[vinorelbine]], [[cisplatin]], [[fluorouracil]]
| |
| |
| |
| |-
| |
| | VIP
| |
| | [[vinblastine]], [[ifosfamide]], [[platinum-based antineoplastic|platinum agent]], ([[etoposide]](VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16)<ref>{{cite journal|last1=El Weshi|first1=A|last2=Memon|first2=M|last3=Raja|first3=M|last4=Bazarbashi|first4=S|last5=Rahal|first5=M|last6=El Foudeh|first6=M|last7=Pai|first7=C|last8=Allam|first8=A|last9=El Hassan|first9=I|last10=Ezzat|first10=A|title=VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.|journal=American journal of clinical oncology|date=October 2004|volume=27|issue=5|pages=529-34|pmid=15596925|url=http://www.ncbi.nlm.nih.gov/pubmed/15596925|accessdate=5 January 2015}}</ref><ref>{{cite journal|last1=Kosmidis|first1=P|last2=Mylonakis|first2=N|last3=Fountzilas|first3=G|last4=Pavlidis|first4=N|last5=Samantas|first5=E|last6=Karabelis|first6=A|last7=Kattis|first7=K|last8=Skarlos|first8=D|title=A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.|journal=Annals of oncology : official journal of the European Society for Medical Oncology / ESMO|date=July 1996|volume=7|issue=5|pages=517-20|pmid=8839908}}</ref>
| |
| | [[testicular cancer]], [[germ cell tumor]]s
| |
| |-
| |
| | VTD-PACE
| |
| | [[bortezomib]] (Velcade), [[thalidomide]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| |
| |
| |
| |-
| |
| |}
| |
| | |
| ==See Also==
| |
| * [[National Comprehensive Cancer Network|National Comprehensive Cancer Network Treatment Guidelines]]
| |
| * [[Breast cancer chemotherapy]]
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| ==External Links==
| |
| * [http://hemonc.org/wiki/Main_Page Chemotherapy regimens and references]
| |
| * [http://chemocare.com/bio/ Chemotherapy side effects]
| |
| * [http://www.christie.nhs.uk/patients/booklets/chemo_index.aspx Christie Hospital Chemotherapy Patient Information Sheets]
| |
| | |
| {{Chemotherapeutic Agents}}
| |